STENTYS (FR0010949404 – STNT), a medical technology company
commercializing in Europe the world's first and only Self-Apposing®
Stent to treat acute myocardial infarction (AMI), announced today
results from the 4-month arm of the APPOSITION IV study of its new
Self-Apposing Sirolimus-eluting stent during the TCT (Transcatheter
Cardiovascular Therapeutics) conference.
The APPOSITION IV trial enrolled 152 patients suffering from
ST-elevation Myocardial Infarction (STEMI) in a double-randomized trial
to compare the STENTYS Sirolimus-eluting stent to Medtronic’s Resolute®
zotarolimus-eluting stent at two different time points, 4 and 9 months,
evaluating stent apposition and strut coverage under intra-vascular OCT
imaging (optical coherence tomography).
Among the 62 patients enrolled in the 4-month group, those treated with
a STENTYS stent had better apposition than the control stent (p=0.006).
The imaging analysis also quantified the number of stent struts
“covered” by tissue, an indication that the endothelium cells lining the
artery wall have grown around the stent and that the vessel has healed.
At 4 months, 32% of the STENTYS stents had all struts already covered
compared to 4% for the Resolute (p=0.03).
“Long-term malapposition and partial strut coverage of drug-eluting
stents have been associated with late stent thrombosis, so the early
healing of vessels treated with STENTYS DES is very good news for our
patients,” said Dr. Robert Jan van Geuns, M.D., Ph.D., Erasmus
Medical Center (Rotterdam, the Netherlands), co-Principal Investigator
of the study, who presented the data.
“These data provide further evidence of the significant benefits that
the Self-Apposing technology can bring to heart attack patients,” said
Gonzague Issenmann, CEO and co-founder of STENTYS. “The Self-Apposing
Sirolimus-eluting stent remains on track for CE Marking and commercial
launch in the second half of 2014.”
The full presentation of results will be available on the STENTYS
website.
About the STENTYS Self-Apposing® Stent
The
STENTYS Self-Apposing® Stent addresses the stent-sizing
dilemma that cardiologists are confronted with when treating heart
attack patients or patients with atypical artery anatomy. Its flexible,
self expanding design takes the shape of the patient’s unique vessel
anatomy and apposes to the irregular contours of a blood vessel, in
particular after an AMI as the vessel dilates and the clot dissolves. It
reduces the risk of malapposition and complications associated with
conventional stents in this setting. The STENTYS Self-Apposing Stent has
been marketed in Europe since receiving CE Mark in 2010. The STENTYS
Sirolimus-eluting stent is expected to receive CE Mark in H2 2014.
About the APPOSITION IV Study
APPOSITION IV is a
prospective, randomized, two-arm, multi-center study designed to compare
the apposition of the STENTYS Sirolimus eluting stent with Medtronic
Resolute® in 150 patients suffering from ST-elevation
Myocardial Infarction. Patients will be followed up at either 4 or 9
months (double randomization). The powered primary endpoint is strut
apposition at 9 months under OCT. The secondary endpoints are strut
apposition at 4 months under OCT and strut coverage at 4 and 9 months.
The final results are expected to be announced in Q2 2014.
About STENTYS
STENTYS is developing and commercializing
innovative solutions for the treatment of patients with acute myocardial
infarction (AMI, or heart attack) and complex coronary artery disease.
STENTYS’s Self-Apposing® Stents are designed to adapt to
vessels with ambiguous or fluctuating diameters, particularly in the
post-infarction phase, in order to prevent the malapposition problems
associated with conventional stents. In the APPOSITION III clinical
trial, STENTYS stents demonstrated a very low one year mortality rate
among 1,000 high-risk AMI patients when compared to recent studies with
conventional stents.
More information is available at www.stentys.com.
This press release contains forward looking statements about the
Company’s business. Such forward looking statements are based on
numerous assumptions regarding the Company’s present and future business
strategies and the environment in which it will operate in the future
which may not be accurate. Such forward-looking statements involve known
and unknown risks which may cause the Company’s actual results,
performance or achievements to differ materially from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among others, risks
associated with the development and commercialization of the Company’s
products, market acceptance of the Company’s products, its ability to
manage growth, the competitive environment in relation to its business
area and markets, its ability to enforce and protect its patents and
proprietary rights, uncertainties related to the U.S. FDA approval
process, including with respect to a pre-market approval for the
Company’s BMS, slower than expected rates of patient recruitment for
clinical trials, the outcome of clinical trials, and other factors,
including those described in the Section 4 “Risk Factors” of the
Company’s 2011 Registration Document (document de référence)
filed with the Autorité des Marchés Financiers in France on
August 27, 2013 under number R.13-040 as such section may be updated
from time to time.
STENTYS is listed on Comp. C of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT
Copyright Business Wire 2013